{"analyses":[{"ciLowerLimit":"0.018","ciPctValue":"95","ciUpperLimit":"1.465","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.105","paramType":"Hazard Ratio (HR)","paramValue":"0.162","statisticalMethod":"Regression, Cox","testedNonInferiority":false},{"ciLowerLimit":"0.143","ciPctValue":"95","ciUpperLimit":"2.289","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.430","paramType":"Hazard Ratio (HR)","paramValue":"0.573","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"Time from study day 1 to first Skeletal Related Event (SRE), defined as \\>1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"NUMBER","populationDescription":"All participants exposed to investigational product during the treatment phase. Median was not reached in at least 1 treatment arm. In lieu of the median, the number of subject who experienced a skeletal related event is presented.","reportingStatus":"POSTED","timeFrame":"Day 1, week 25","title":"Time to First Skeletal Related Event","type":"SECONDARY","unitOfMeasure":"Participants"}